We are a clinical stage, global company, focused on high unmet clinical needs where oral delivery of a protein therapy can significantly improve the standard of care
We are developing first-in-class, daily tablet protein and peptide replacement therapies, designed for patients to live healthier and injection-free, as they manage their chronic diseases. Our goal is for our small, oral protein tablets to change treatment outcomes for patients globally.
Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, which leads to greater fragility and an increase in fracture risk.
Our 2018 license agreement with Amgen, we are developing oral formulations of novel therapeutic protein candidates.
© 2020 EnteraBio Ltd.